🟢 DFTX is trading 4.2% up today on Oppenheimer upgrade and DT120 trial progress

DFTX is trading 4.2% up at $48.52 following a recent Oppenheimer upgrade to a $60 price target and positive DT120 clinical trial progress.

• The move extends a sharp multi-day rally driven by Phase 3 momentum and bullish analyst sentiment ahead of upcoming DT120 topline readouts.
• The company maintains a robust cash runway into 2028, providing significant financial stability for its ongoing clinical programs.